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roteoglycans participate in growth factor interaction
with the cell surface through their heparan sulfate
chains (HS), but it is not known if they are otherwise
involved in growth factor signaling. It appears now that the
syndecan-4 core protein, a transmembrane proteoglycan
shown previously to bind phosphatidylinositol 4,5-bisphos-
phate (PIP
 
2
 
) and activate PKC
 
 
 
, participates in mediating
the effects of ﬁbroblast growth factor (FGF)2 on cell function.
Mutations in the cytoplasmic tail of syndecan-4 that ei-
 
ther reduced its afﬁnity to PIP
 
2
 
 (PIP
 
2
 
 
 
) or disrupted its
postsynaptic density 95, disk large, zona occludens-1
 
(PDZ)-dependent binding (PDZ
 
 
 
) produced a FGF2-speciﬁc
dominant negative phenotype in endothelial cells as evi-
P
 
denced by the marked decline of their migration and pro-
liferation rates and the impairment of their capacity to
 
form tubes. In both cases, the molecular mechanism was
determined to consist of a decrease in the syndecan-4–
 
dependent activation of PKC
 
 
 
. This decrease was caused
either by inhibition of FGF2-induced syndecan-4 de-
 
phosphorylation in the case of the PDZ
 
 
 
 mutation or by
disruption of basolateral targeting of syndecan-4 and its
associated PDZ-dependent complex in the case of the
 
PIP
 
2
 
 
 
 mutation. These results suggest that PKC
 
 
 
 activation
and PDZ-mediated formation of a serine/threonine phos-
phatase-containing complex by syndecan-4 are downstream
events of FGF2 signaling.
 
Introduction
 
The participation of heparan sulfate
 
 
 
(HS)* chains in binding
numerous soluble ligands and extracellular matrix proteins
(Bernfield et al., 1999) drew increased attention once HS
presence on the cell surface was shown to be required for
fibroblast growth factor (FGF)2-dependent cell growth
(Rapraeger et al., 1991). The list of HS-binding soluble
ligands has grown significantly, culminating recently in the
finding that syndecan-1–attached HS chains promote the
tumorigenic response to Wnt-1 (Alexander et al., 2000).
The potential role of the HS-carrying core of the pro-
teoglycans in mediating the cellular response to growth
factors received little attention, however, despite earlier
indications of their response to extracellular signals, such
as the recruitment of syndecan-4 to focal adhesions (Woods
and Couchman, 1994; Baciu and Goetinck, 1995). The
possibility of fulfilling specific functional roles seems partic-
ularly relevant to the syndecan core proteins, all of which
share a distinct and highly conserved cytoplasmic tail. One
of the motifs common to all the syndecans is a COOH-ter-
minal postsynaptic density 95, disk large, zona occludens-1
(PDZ)-binding motif now known to bind at least four PDZ
domain–containing partners (Grootjans et al., 1997; Cohen
et al., 1998; Hsueh et al., 1998; Ethell et al., 2000; Gao et
al., 2000). Similar to other PDZ proteins, these binding part-
ners very likely serve as adaptors between the syndecans and
additional members of larger complexes.
Syndecan-4, the most widely spread member of the family,
differs in its sequence from the other three syndecans by
a unique phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
)–
binding seven-residue motif located in the middle of its
28–amino acid–long cytoplasmic tail (Lee et al., 1998;
Horowitz et al., 1999). Syndecan-4 has been implicated in
signal transduction (Volk et al., 1999) and the activation of
PKC
 
 
 
 (Oh et al., 1997b). PIP
 
2
 
 appears to underlie the
signaling activity of the cytoplasmic tail of syndecan-4, serving
as a binding interface (Horowitz et al., 1999), an essential co-
factor for PKC
 
 
 
 activation (Oh et al., 1998), and a facilitator of
the tail’s multimerization (Oh et al., 1997a). These properties
are regulated by the phosphorylation of S
 
183 
 
located four
residues away from the NH
 
2 
 
terminus of the PIP
 
2
 
-binding
motif (Horowitz and Simons, 1998a). Once phosphory-
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lated, the affinity of the cytoplasmic tail for PIP
 
2
 
 and its capac-
ities to oligomerize and activate PKC
 
 
 
 in the presence of PIP
 
2
 
are sharply reduced (Simons and Horowitz, 2001).
Given the HS dependence of the activity of several growth
factors and the in vivo–observed increase in syndecan-4 ex-
pression during growth factor-regulated healing from injury
(Gallo et al., 1994; Nikkari et al., 1994; Li et al., 1997), we
asked whether the molecular attributes of syndecan-4 listed
above are relevant to growth factor signaling. Using FGF2 as
an HS-binding growth factor prototype, we found that dis-
ruption of either the PIP
 
2
 
 or PDZ-binding domains of syn-
decan-4 conferred a dominant negative phenotype in regard
to this growth factor but not to serum or epithelial growth
factor (EGF)- and PDGF-induced response.
Therefore, these data suggest that syndecan-4 selectively
regulates FGF2 signaling in endothelial cells.
 
Results
 
Site-directed mutations in syndecan-4 confer dominant 
negative effects on FGF2 signaling in endothelial cells
 
We addressed the potential role of syndecan-4 in regulating
the cellular response to FGF2 by transfecting rat fat pad en-
dothelial cells (RFPECs), which express syndecan-4 endoge-
nously (Kojima et al., 1992), with hemagglutinin (HA)-
tagged wild-type (WT) (S4) syndecan-4 or with HA-tagged
syndecan-4 constructs mutated at two key sites (Fig. 1 A). In
the first construct (PIP
 
2
 
 
 
), the three consecutive residues
Y
 
192
 
KK in the cytoplasmic tail of syndecan-4 were mutated
to LQQ, a mutation that drastically reduces the PIP
 
2
 
 affinity
of the cytoplasmic tail and inhibits its PIP
 
2
 
-mediated activa-
tion of PKC
 
 
 
 (Horowitz et al., 1999). In another construct
(PDZ
 
 
 
), the COOH-terminal residue (A
 
202
 
) was deleted,
thereby abolishing PDZ-dependent binding of syndecan-4
(Songyang et al., 1997). Finally, a PIP
 
2
 
 
 
/PDZ
 
 
 
 construct
combined the features of the other two constructs.
To measure the expression level of the introduced constructs
and the effect of exogenous construct expression on endoge-
nous syndecan-4 levels, we immunoblotted total cell lysates
from each of the cell lines with antibodies to syndecan-4 and
HA (Fig. 1 B). The syndecan-4 immunoblot represents the
sum of endogenous and transfected syndecan-4 proteins,
whereas the HA immunoblot assesses the amount of trans-
fected syndecan-4. The immunoblots showed on average a
twofold increase in the expression level of the exogenous con-
structs over the endogenous syndecan-4 protein in the trans-
fected cell lines, excluding the PIP
 
2
 
 
 
 cells where the mutated
syndecan-4 variant is not recognized by the antibody against
the cytoplasmic tail used in these experiments, since the LQQ
mutation disrupts its epitope (unpublished data).
To find whether these mutations perturbed FGF2 signal-
ing, we examined several potentially susceptible cell func-
tions. Migration rate in response to FGF2 treatment was
measured by a wounding assay of confluent cell monolay-
ers. The migration rates of cells expressing either PIP
 
2
 
 
 
 or
PDZ
 
 
 
 syndecan-4 mutants were similar to each other and
threefold lower than the migration rate of vector-trans-
fected RFPECs (Fig. 2 A). At the same time, migration of
cells carrying the combined PIP
 
2
 
 
 
/PDZ
 
 
 
 mutation was not
different from controls. In agreement with our previous
observations (Volk et al., 1999), the migration rate of
RFPECs overexpressing S4 was even higher than vector-
transfected cells (relative gap closure of 0.34 
 
 
 
 0.09 versus
0.27 
 
 
 
 0.03, respectively; 
 
n
 
 
 
  
 
12, 
 
p
 
 
 
  
 
0.023). Cell growth
in response to FGF2 over a period of 3 d was measured by
proliferation assays with the same cell clones used in the mi-
gration assays. Cells expressing either the PIP
 
2
 
 
 
 or PDZ
 
 
 
mutants had 3–5-fold lower proliferation rates in compari-
son to vector-transfected cells, whereas cells expressing the
Figure 1. Syndecan-4 mutants and their expression level in RFPECs. 
(A) Schemes of syndecan-4 cytoplasmic tail constructs used in the 
study. From left to right: WT cytoplasmic tail (S4, solid cylinder; 
PIP2-binding domain, solid sphere; COOH-terminal A
202 residue), 
PIP2
  (Y
192KK to LQQ) mutation (void cylinder), PDZ
  (deletion of the 
COOH-terminal A
202 residue) mutation, and PIP2
 /PDZ
  (combination 
of both mutations). (B) Protein levels of exogenous and endogenous 
syndecan-4 in transfected cell clones. (Top) Immunoblots for total 
syndecan-4 protein levels using antiserum specific to the cytoplasmic 
tail of syndecan-4, and a histogram representing the densitometric 
values of each band (in arbitrary units). (Bottom) As above, using 
HA tag antibody. Aliquots of cell lysate containing equal masses of 
total protein were immunoprecipitated from each cell group with 
antiserum specific to the ectoplasmic tail of syndecan-4. 
Glycosaminoglycan chains were digested before gel electrophoresis. 
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PIP
 
2
 
 
 
/PDZ
 
 
 
 mutation had the same proliferation rate as
vector controls, a pattern similar to the results of the migra-
tion assays (Fig. 2 B). Finally, tube formation on extracellu-
lar matrix basement in response to FGF2 by cell clones ex-
pressing the PIP
 
2
 
 
 
 or PDZ
 
 
 
 syndecan-4 mutations, but not
the PIP
 
2
 
 
 
/PDZ
 
 
 
 mutation, was also markedly impaired in
comparison with the continuous and articulated tube net-
works formed by vector-transfected cells (Fig. 2 C) or by
S4-overexpressing RFPECs (unpublished data).
The combined results of the migration, proliferation, and
tube formation experiments indicate that both the LQQ
substitution and the A
 
202
 
 deletion conferred a dominant
negative phenotype on RFPECs when coexpressed with en-
dogenous syndecan-4. This effect was FGF2 specific, since
when performed in the presence of 10% serum (Fig. 2, A
and C) or in the presence of either EGF or PDGF AB (25
ng/ml each [unpublished data]) migration and tube forma-
tion by PIP
 
2
 
 
 
 and PDZ
 
 
 
 cells did not differ from those of
vector-transfected cells.
 
PIP
 
2
 
 
 
 mutation impairs syndecan-4 targeting to the 
basolateral region
 
To elucidate the mechanism of the dominant negative effect
of the mutations in the cytoplasmic tail of syndecan-4, we
compared the cellular distribution of each mutated synde-
can-4 variant to that of the endogenous molecule. Staining
of untransfected RFPECs with the antibody to syndecan-4
demonstrated the presence of the proteoglycan along the cell
borders and in the perinuclear region (Fig. 3, top). S4 ex-
pressed in RFPECs assumed a similar distribution (Fig. 3,
bottom). The perinuclear location coincided with the Golgi
apparatus as shown by overlap with the staining for the
Golgi scaffold protein GM130 (Nakamura et al., 1995).
Both the PIP
 
2
 
 
 
 and PIP
 
2
 
 
 
/PDZ
 
 
 
 syndecan-4 variants
maintained their Golgi localization but were no longer
present in the basolateral region (Fig. 4, A and C, respec-
tively). In contrast with the cellular distribution of the
PIP
 
2
 
 
 
 and PIP
 
2
 
 
 
/PDZ
 
 
 
 syndecan-4 mutants, the distribu-
tion of the PDZ
 
 
 
 mutant (Fig. 4 B) did not differ from
that of the endogenous syndecan-4, indicating that synde-
can-4 is targeted to the basolateral region by its association
with PIP
 
2 
 
rather than with a PDZ protein.
 
Figure 2.
 
Effects of syndecan-4 mutations on cell function. 
 
(A) 
Migration of RFPECs as measured in “wounding” assays (inset). Cells 
were starved in 0.5% FBS for 24 h, scratched, and incubated for 
another 6 h either with 0.5% FBS and 20 ng/ml FGF2 (black bars) or 
with 10% FBS alone (white bars). Gap size was measured immediately 
before (W
 
0
 
) and after (W
 
6
 
) the 6-h incubation period (
 
 
 
W 
 
  
 
W
 
0 
 
  
 
W
 
6
 
). 
Data shown as mean 
 
 
 
 SD (
 
n
 
 
 
  
 
12 
 
  
 
18; *
 
p
 
 
 
  
 
0.05). (B) Fold 
increase in cell number relative to day 0 as measured in RFPEC 
proliferation assays. Cells were starved as above and then treated 
with 20 ng/ml FGF2 (
 
n
 
 
 
  
 
3). Cells were counted immediately before 
FGF2 application and at 24, 48, and 72 h after it. Data shown as 
mean 
 
 
 
 SD (n 
 
  
 
4; *
 
p 
 
  
 
0.05 [
 
 
 
,
 
 
 
vector-transfected control cells; 
 
 
 
, PIP
 
2
 
 
 
 cells; 
 
 
 
, PDZ
 
 
 
 cells; 
 
 
 
, PIP
 
2
 
 
 
/PDZ
 
 
 
 cells]). (C) Tube 
formation assays on extracellular matrix basement (Matrigel™; 
Beckton Dickinson). Cells were starved as above, then treated for
24 h either with 0.5% FBS and 20 ng/ml FGF2 or with 10% FBS alone 
(insets), and imaged immediately. Each cell line was assayed in 
duplicate. Note that all cell lines formed normal tube networks when 
treated with 10% FBS. 
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To further examine the effect of the PIP
 
2
 
 
 
 mutation on the
surface targeting of syndecan-4, the S4, PIP
 
2
 
 
 
, and PIP
 
2
 
 
 
/
PDZ
 
 
 
 variants were transfected into RFPECs via a bicistronic
enhanced green fluorescent protein (EGFP)-expressing plas-
mid. Each cell group was scanned at both 488 nm, the EGFP
emission wavelength, and 580 nm, the emission wavelength
of the red pycoerythrin (R-PE) fluorophore conjugated to the
secondary antibody used to detect the HA-tagged exogenous
syndecan-4. As shown in Fig. 5 A, cells transfected by S4 (Fig.
5 A, b) had high counts at both wavelengths, whereas cells ex-
pressing the PIP
 
2
 
 
 
 and PIP
 
2
 
 
 
/PDZ
 
 
 
 mutants (Fig. 5 A, c and
d, respectively) had low counts at 580 nm similar to the vec-
tor-transfected control cells (Fig. 5 A, a). Note that though
the fraction of EGFP-expressing cells out of the total PIP
 
2
 
 
 
cell population is low relative to the EGFP-expressing frac-
tions in the other three the cell populations, the ratio between
the cell fraction expressing both EGFP and PIP
 
2
 
 
 
 and the
fraction expressing only EGFP (1:20) is similar to the corre-
sponding ratio (1:25) in the PIP
 
2
 /PDZ
  cell population,
whereas the ratio in the S4 cell population is much higher
(1:3). These results confirm the conclusion drawn from the
immunofluorescence experiments that the PIP2
  syndecan-4
mutant is not present on the cell surface.
The sequestration of the PIP2
 -mutated syndecan-4 to the
Golgi apparatus may potentially reduce the presence of endoge-
nous syndecan-4 on the cell surface if the two could form het-
erooligomers. In that case, the lower responses of the PIP2
  cells
to FGF2 observed in the functional assays (Fig. 2) may result
not only from the presence of the mutated form of syndecan-4,
but more trivially, from the resulting deficit in the available
FGF-binding sites along the syndecan-4–associated HS chains.
To test this possibility, we quantified the amount of syndecan-4
present on the cell surface in vector-transfected and PIP2
  cells
by fluorescence-assisted cell sorting (FACS) using an antibody
against the ectoplasmic domain of syndecan-4. Since we have
shown already (Fig. 4 A and Fig. 5 A) that the PIP2
  variant of
Figure 3. Cellular distribution of endogenous and 
transfected syndecan-4 in RFPECs. (Top) Phase (left) 
and immunofluorescence (right) images of the same 
untransfected RFPECs labeled with 1:50 diluted 
syndecan-4 cytoplasmic tail antiserum. Arrows 
point to the Golgi apparatus, and arrowheads point 
to cell junctions. Nuclear staining on the right is 
due to nonspecific immunolabeling. (Bottom) Confocal 
immunofluorescence images of RFPECs doubly labeled 
with 1  g/ml HA antibody (Roche) and 2.5  g/ml 
antibody to GM130 (Transduction Laboratories), 
showing the distribution of HA-tagged WT syndecan-4 
(S4, left), GM-130 Golgi marker (middle), and an overlay 
of both images. Bars, 25  m. Note the distribution of 
both endogenous and WT overexpressed syndecan-4 
(S4) along cell junctions and in the Golgi apparatus.
Figure 4. The distribution of syndecan-4 mutants in RFPECs. 
(A) PIP2
 -expressing cells doubly immunolabeled with syndecan-4 
cytoplasmic tail antiserum (left) and HA antibody (middle). Note 
that the distribution of the PIP2
  syndecan-4 (middle) was 
restricted to the Golgi, whereas native syndecan-4 (left) is 
localized both to the Golgi and along cell borders as in the top 
right of Fig. 3. Nuclei appear in this and in B and C due to 
nonspecific binding of the syndecan-4 antiserum. (B) PDZ
  cells 
doubly immunolabeled with syndecan-4 cytoplasmic tail antiserum 
(left) and HA antibody (middle). Note that the distribution of the 
PDZ
  syndecan-4 was similar to that of HA-tagged WT syndecan-4 
in Fig. 3, bottom left. (C) PIP2
 /PDZ
  cells doubly immunolabeled 
with syndecan-4 cytoplasmic tail antiserum (left) and HA 
antibody (middle). Note that the distribution of the PIP2
 /PDZ
  
syndecan-4 was similar to that of PIP2
  syndecan-4 in Fig. 4 A, 
middle. Panels on the right are overlays of the left and middle. 
Bar, 25  m. FGF2 effects and syndecan-4 | Horowitz et al. 719
syndecan-4 is not present on the cell surface, the antibody
would detect only the endogenous syndecan-4. The FACS re-
sults (Fig. 5 B) show no significant differences between the
amounts of syndecan-4 molecules present on the surface of vec-
tor-transfected and PIP2
  cells.
PIP2
  and PDZ
  mutations reduce 
syndecan-4–associated activity of PKC 
An established signaling role of syndecan-4 is the modula-
tion of FGF2-stimulated PIP2-dependent PKC  activity
(Oh et al., 1997b; Horowitz and Simons, 1998a). Since the
activity of this PKC isoenzyme has been linked previously to
the promotion of cell growth (Kolch et al., 1993, 1996; Cai
et al., 1997; Schonwasser et al., 1998; Lallena et al., 1999;
Besson and Yong, 2000), migration (Harrington et al.,
1997), and tube formation (Wang et al., 2002), we studied
the effect of PIP2
  and PDZ
  mutations on PKC  activity
in these cells. To this end, we assayed the activity of PKC 
coimmunoprecipitated with HA-tagged syndecan-4 core
proteins from the RFPEC clones expressing S4, PIP2
 ,
PDZ
 , or PIP2
 /PDZ
  syndecan-4 constructs, before and
after FGF2 stimulation.
Figure 5. FACS
® analysis of exogenous and 
endogenous syndecan-4 expression levels. (A) 
Distributions of pIRES2-EGFP vector-transfected 
(a), HA-WT–overexpressing (b), PIP2
 -transfected 
(c), and PIP2
 /PDZ
 -transfected cells (d) as a 
function of their fluorescence intensities at 488 
nm (EGFP, horizontal axis, arbitrary units [AU]) 
and at 580 nm (R-PE, vertical axis), corresponding 
to the EGFP levels expressed either alone (a) or in 
tandem with each syndecan-4 variant (b, c, and 
d) and to the cell surface expression levels of the 
syndecan-4 variants, respectively. The quadrants 
were drawn so as to enclose near to 100% of 
control nontransfected cells (unpublished data) 
in the lower right quadrant. Numbers in the 
corners denote the percentage of the cell population 
in each quadrant. Quasi colors denote count 
density (red, high; blue, low). (B) Intensity distribution 
(in arbitrary units) of cells labeled with antiserum to 
the syndecan-4 ectoplasmic domain followed by 
anti–rabbit IgG-Alexa 594, showing the levels of 
cell surface expression of endogenous syndecan-4 
in vector-transfected (a) and PIP2
 -expressing (b) 
cell lines.720 The Journal of Cell Biology | Volume 157, Number 4, 2002
FGF2 treatment increased syndecan-4/PIP2-dependent PKC 
activity eightfold in syndecan-4–overexpressing RFPECs rela-
tive to untreated cells of the same type (Fig. 6 A). On the
other hand, syndecan-4–dependent PKC  activity in cells ex-
pressing PIP2
 , PDZ
 , or PIP2
 /PDZ
  syndecan-4 constructs
was not increased by FGF2. No significant FGF2-induced rela-
tive increases in syndecan-4–associated kinase activities were ob-
served when instead of PIP2 the assays were done in the pres-
ence of Ca
2 , diacylglycerol, and phosphatidylserine. The
absolute level of the Ca
2 -dependent activity of PKC  is typi-
cally higher by 20% than its activity in the presence of PIP2 and
the cytoplasmic tail of syndecan-4 (Horowitz and Simons,
1998a). The fact that the Ca
2 -dependent PKC  activities of
all of the cell lines tested did not significantly differ from each
other (Fig. 6 A), either with or without FGF2 treatment, indi-
cates that similar amounts of PKC  were immunoprecipitated
in all cases. Similar to the functional assays described above, the
increase in the syndecan-4–associated kinase activity was spe-
cific to FGF2, since no significant differences were found be-
tween the syndecan-4–associated kinase activities in serum-
treated versus untreated cells. Since the kinase activities were
measured ratiometrically for each cell line (FGF2 or serum-
treated versus untreated cells), they were not affected by varia-
tions between different cell lines in the absolute amounts of syn-
decan-4–associated PKC .
Though the binding of PKC  to the cytoplasmic tail of
syndecan-4 is well documented (Oh et al., 1997b; Horowitz
and Simons, 1998a), we verified that the measured kinase
activity in these assays was produced by a calcium-depen-
dent PKC and not by other unidentified syndecan-4–associ-
ated kinases. Both the highly specific PKC autoinhibitor
peptide (House and Kemp, 1987) and the cPKC inhibitor
Gö6976 (Martiny-Baron et al., 1993) effectively suppressed
the syndecan-4–associated kinase activity (Fig. 6 B).
PDZ
  syndecan-4 is hyperphosphorylated after 
FGF2 stimulation
Surprisingly, the FGF2-stimulated PKC  activity in cells trans-
fected with the PDZ
  mutant was similar to that seen in cells
transfected with the PIP2
  mutant and much lower than in cells
transfected with the native syndecan-4 construct (Fig. 6 A).
Given that the capacity of syndecan-4 to activate PKC  is
sharply reduced by the phosphorylation of S
183 in its cytoplas-
Figure 6. Syndecan-4–associated kinase activities. (A) Relative kinase 
activities of HA immunoprecipitates from RFPECs starved in 0.5% FBS 
for 24 h and then incubated for another 20 min either without or with 
20 ng/ml FGF2, or with 10% FBS. Data shown is mean   SD (n   3) of 
the ratios between the kinase activity immunoprecipitated from FGF2- 
or FBS-treated cells and from nontreated cells of the same type. Note 
that the kinase activity of S4 cells was increased significantly by FGF2 
treatment relative to other cell lines and that this relative increase was 
observed only when the immunoprecipitates where assayed in the 
presence of PIP2
  but not when assayed in the presence of Ca
2 , 
phosphatidylserine, and diolein. Note also that the PIP2-dependent 
kinase activities immunoprecipitated from S4 and PIP2
 -expressing 
cells did not significantly differ from each other when cells were 
treated with FBS instead of FGF2 (black bars, S4 cells; light gray bars, 
PIP2
  cells; white bars, PDZ
  cells; dark gray bars, PIP2
 /PDZ
  cells). 
(B) Effects of PKC autoinhibitor peptide (AIP, 100 nM) or of Gö6976 
(10 nM) on kinase activities (mean   SD, n   3) of anti-HA immuno-
precipitates from RFPECs in the presence of Ca
2 , phosphatidylserine, 
and diolein. Results are relative to the kinase activity of untreated 
control samples (insets in A and B are representative phosphoimages of 
PKC I optimal substrate peptide bands used for quantifying the kinase 
activities of anti-HA precipitates).
Figure 7. Phosphorylation levels of syndecan-4. Data shown is 
means   SD (n   3) of syndecan-4 phosphorylation levels measured 
as described in Materials and methods. Cells were incubated in 0.5% 
FBS either without (black bars) or with (white bars) 20 ng/ml FGF2 
starting 2 h before radio labeling for a total of 4 h. Note the significant 
difference (*p   0.05) between the phosphorylation levels of S4 
and PDZ
  before and after FGF2 treatment (tot, total syndecan-4 
population in the cell). (Insets) Immunoblots of representative 
samples from each cell group and condition. FGF2 effects and syndecan-4 | Horowitz et al. 721
mic tail (Horowitz and Simons, 1998a), we compared the effect
of FGF2 stimulation on the phosphorylation level of the PDZ
 
mutant to its effect on the S4 variant. FGF2 administration
lowered the phosphorylation levels of S4 in a statistically signifi-
cant manner (Fig. 7) relative to its basal level, in agreement with
previously described results (Horowitz and Simons, 1998a), but
it did not lower those of the PDZ
  mutant. Moreover, the
phosphorylation level of the PDZ
  mutant after FGF2 treat-
ment was significantly higher than its basal level. This increase
may reflect the dependence of the phosphorylation level on a
dynamic balance between the opposing actions of a kinase and a
phosphatase. The dephosphorylation of the PDZ
  mutant
would be impaired if the association of syndecan-4 with the pu-
tative phosphatase was mediated by a PDZ adaptor protein.
Consequently, the activity of the kinase that phosphorylates
Ser
183, which could conceivably be elevated by FGF2, would be
unopposed by the phosphatase, resulting in an effective increase
in the phosphorylation level of syndecan-4.
Since it is likely that the PDZ
  mutant and the endoge-
nous syndecan-4 copolymerize, the abolishment of the bind-
ing of the putative phosphatase may affect the phosphoryla-
tion levels of both syndecan-4 variants. Since the currently
available antibodies cannot separate between the endoge-
nous and the exogenous syndecan-4 species, we were able to
measure the effect of FGF2 on the phosphorylation level
of only the total syndecan-4 population, which was not
changed significantly (Fig. 7). This outcome could be attrib-
uted to opposing and mutually canceling changes in the
phosphorylation levels of the endogenous and PDZ synde-
can-4 populations in response to FGF2, thus implying that
the expression of the PDZ
  mutant did not significantly af-
fect the phosphorylation level of endogenous syndecan-4.
PIP2
  mutation reduces syndecan-4 PIP2-dependent 
oligomerization and activation of PKC 
The capacity of syndecan-4 to activate PKC  is depen-
dent on its affinity to PIP2 and on its tendency to oligo-
merize in the presence of this phosphoinositide (Horo-
witz and Simons, 1998a). The potent suppression of PKC 
activity and of several cell functions by the LQQ muta-
tion implies that the PIP2
  mutant has a dominant nega-
tive effect when expressed on a background of endoge-
nous syndecan-4. Therefore, we investigated the effect of
mixing PIP2
 -mutated cytoplasmic syndecan-4 tail pep-
tide with the WT tail peptide on the combined affinity of
the mixture to PIP2 in vitro. As little as 25% of PIP2
 
peptide in the total WT/PIP2
  mixture increased the ap-
parent KD of the mixture by three orders of magnitude
increasing the PIP2
  peptide fraction. (B) Column elution profiles 
of WT (top) and PIP2
  (bottom) cytoplasmic tail peptides with 
(continuous line) and without (dashed line) PIP2. Note the formation 
of high-order oligomers by the WT (arrow) but not by the PIP2
  
peptide in the presence of PIP2. Note also that both peptides are not 
present as monomers but form smaller oligomers of similar sizes 
both in the presence and absence of PIP2. (C) Dependence of the in 
vitro activity of recombinant PKC  on PIP2 concentration in the 
absence ( ) and the presence of 1  M WT ( ), PIP2
  ( ), or PDZ
  ( ) 
cytoplasmic tail peptides (mean   SD, n   3–6; *p   0.05). The 
mean kinase activity measured at 1  M PIP2 with 1  M WT peptide 
was used as a unitary reference value.
Figure 8. In vitro experiments with synthetic WT and mutated 
syndecan-4 cytoplasmic tail peptides. (A) Dependence of surface 
plasmon resonance-measured apparent first-order equilibrium 
constants (KD) between PIP2 and PIP2
 /WT peptide mixtures on 
PIP2
  peptide fraction. Note the gradual elevation in KD value upon 722 The Journal of Cell Biology | Volume 157, Number 4, 2002
compared with that of the WT peptide alone as measured
by surface plasmon resonance (Fig. 8 A).
Since syndecan-4–PIP2 binding is thought to play a role in
the oligomerization of syndecan-4 tails (Oh et al., 1997a;
Horowitz and Simons, 1998a), we examined the oligomeriza-
tion capacity of the PIP2
  peptide. When resolved by column
chromatography, the PIP2
  peptides did not form high-order
oligomers in the presence of PIP2 unlike the WT peptides (Fig.
8 B). However, both peptides formed smaller PIP2-indepen-
dent oligomers of a size between tetramers and hexamers. The
capacity of the PIP2 peptide to form low-order oligomers in the
same manner as the WT peptide may explain the significantly
higher KD between PIP2 and the 25%:75% PIP2
  to WT pep-
tide mixture reported above, since the two peptides could form
heterooligomers of a PIP2 affinity much lower than that of WT
homooligomers due to the presence of the PIP2
  peptide. The
decreased affinity of the PIP2
  peptide to PIP2 and its lower ten-
dency to oligomerize were accompanied by a large reduction in
its capacity to activate PKC  in the presence of PIP2 relative to
the WT peptide (Fig. 8 C). Though the PDZ
  peptide is
shorter than the WT peptide only by a single residue, the
COOH-terminal alanine, the PKC  activity in its presence at
2.5  M   PIP2   10  M was lower in a statistically significant
manner than the corresponding activities in the presence of the
WT peptide but higher than those of the PIP2
  mutant.
Discussion
We have described a novel mechanism regulating growth factor
signaling, distinctive both for its specificity to FGF2 (versus se-
rum, EGF, and PDGF) and for the pivotal role of syndecan-4.
The main feature of this signaling pathway is activation of
PKC  by the syndecan-4–PIP2 complex in response to FGF2
stimulation. This process is controlled by the phosphorylation
of S
183 in the cytoplasmic tail of syndecan-4 that down-regulates
the response to FGF2 by preventing PIP2-dependent oligomer-
ization of syndecan-4 and the subsequent activation of PKC .
Our working model of this mechanism (Fig. 9) consists of
the following steps. (a) FGF2 binding to its high affinity tyro-
sine kinase receptor induces the activation of a putative serine/
threonine protein phosphatase type 1/2A (PP1/2A) (Horowitz
and Simons, 1998b), which is associated with the cytoplasmic
tail of syndecan-4 through a PDZ adaptor protein. (b) The
PP1/2A dephosphorylates Ser
183 in the membrane proximal do-
main of the syndecan-4 cytoplasmic tail, which is normally
maintained at a high basal phosphorylation level. Since the HS
chains carried by proteoglycans can reach estimated lengths of
80 nm (Kato et al., 1994), the dephosphorylation is likely to oc-
cur in a trans rather than a cis mode in regard to the syndecan-4
molecule carrying the FGF2-binding HS chain. Since synde-
can-4 is a transmembrane protein, this dephosphorylation may
similarly occur in the Golgi-residing syndecan-4. (c) Dephos-
phorylation of syndecan-4 sharply increases its affinity to PIP2
(Horowitz and Simons, 1998a). In turn, PIP2 binding facilitates
the multimerization of syndecan-4. (d) The clustered syndecan-
4–PIP2 complex activates PKC , which associates with synde-
can-4 through PIP2 (Horowitz et al., 1999).
The existence of this regulatory mechanism is suggested by
our observations that expression of PIP2
  or PDZ
  syndecan-4
mutants on a background of endogenous syndecan-4 inhib-
its cell response to FGF2 but not to serum or the HS binding
EGF and PDGF AB in a dominant negative manner. In the
case of the PIP2
  mutation, the mistargeting of the mutant
syndecan-4 leads to Golgi sequestration of its PDZ-binding
partner. The critical role of this sequestration is emphasized
by the lack of dominant negative effects of the double PIP2
 /
PDZ
  syndecan-4 mutation. In the case of the PDZ
  dele-
tion, FGF2 treatment would lead to an increase in the extent
of syndecan-4 phosphorylation and consequently would de-
crease PKC  activation due to the low affinity of phosphory-
lated syndecan-4 for PIP2 (Horowitz et al., 1999).
A recent study on syndecan-4 knockout mice reported that
the proliferative response of skin fibroblasts extracted from
these mice did not differ from the response of cells from WT
mice (Echtermeyer et al., 2001). The difference between this
finding and the significantly reduced proliferation rates of
cells expressing the PIP2
  or PDZ
  syndecan-4 mutants that
we observed may stem from each of the following reasons. (a)
As explained above, the expression of these mutants interferes
with the function of endogenous syndecan-4. This active per-
turbation of a signaling pathway was not present in the mouse
syndecan-4
 /  cells. (b) Differences between cell types (fibro-
blasts versus endothelial cells) used in the two studies. (c) As-
suming that Echtermeyer et al. (2001) used the same medium
as in their migration assays (the medium used in their prolifer-
ation assays is not described), the 2% serum present in this
Figure 9. Schematic representation of 
FGF2 signal transduction mediated by 
syndecan-4. FGFR, FGF2 tyrosine 
kinase receptor; CS, chondroitin sulfate 
side chains. See Discussion for details. FGF2 effects and syndecan-4 | Horowitz et al. 723
medium may have contained other growth factors that com-
pensated for the impaired response to FGF2.
PIP2
  mutation: effect on plasma membrane targeting 
of syndecan-4
One interesting and unexpected finding in this study is the
fact that PIP2 binding rather than the interaction with a
PDZ protein targets syndecan-4 to the plasma membrane.
The data supporting this observation include immunofluo-
rescence staining showing reduced expression of the PIP2
 
and PIP2
 /PDZ
  mutants in the basolateral region and vir-
tual absence of syndecan-4 variants containing the PIP2
 
mutation from the cell surface as demonstrated by FACS.
Similarly, deletion of the PDZ motif in the syndecan-2 cyto-
plasmic tail did not eliminate its incorporation into the
plasma membrane (Ethell and Yamaguchi, 1999).
The Golgi apparatus is a known site of PIP2 synthesis
(Godi et al., 1999; Jones et al., 2000), and the involvement
of PIP2 in protein sorting is suggested by preliminary obser-
vations (Morrow, M.W. and P. Weidman, 2000. Mol. Biol.
Cell. 11:S280a). However, the actual targeting mechanism is
still unknown. The results of the FACS experiments (Fig. 5
A) show that the PIP2
  mutation precluded not only the ba-
solateral targeting but also the overall incorporation of syn-
decan-4 in the plasma membrane.
The dominant negative phenotype exhibited by the PIP2
 
mutant suggests that it disrupts a syndecan-4–dependent pro-
tein complex involved in mediating FGF2 signaling. Interest-
ingly, it is the presence of the PIP2
  mutant and not a mere ab-
sence of syndecan-4 from the cell that impairs cellular function.
This conclusion is supported by studies of the PIP2
 /PDZ
 
mutant that does not cause a similar dominant negative pheno-
type, yet it is similarly absent from the plasma membrane (Fig.
4 C), and by a recently described syndecan-4 knockout mouse
(Ishiguro et al., 2000). Instead, we propose that the dominant
negative effect of the PIP2
  mutation is caused by sequestration
to the Golgi apparatus of a syndecan-4–binding PDZ protein
specifically involved in FGF2 (and not serum, EGF, or PDGF)
signaling. Assuming that FGF2 signaling requires the presence
of this syndecan-4–bound PDZ protein in the basolateral re-
gion, the PIP2
  mutant may compete with endogenous synde-
can-4 for binding to the PDZ protein, thus capturing a large
part of this protein population at the Golgi apparatus and inter-
fering with its targeting to the plasma membrane and the for-
mation of a syndecan-4–dependent complex.
PDZ binding regulates syndecan-4 phosphorylation in 
response to FGF2
We have shown that the dominant negative effect of the
PDZ
  mutation is associated with increased phosphorylation
of the PDZ
  syndecan-4 mutant after FGF2 treatment. The
phosphorylation state of syndecan-4 is controlled on one hand
by a novel PKC (nPKC) and on the other by a FGF2-acti-
vated PP1/2A (Horowitz and Simons, 1998b). Since the
phosphorylation level of the PDZ
  mutant was significantly
higher than that of S4 after FGF2 treatment, the most likely
explanation for this observation is impaired dephosphoryla-
tion of the PDZ
  mutant, resulting in unopposed activity of
the nPKC. This in turn suggests that the PP1/2A involved in
syndecan-4 dephosphorylation forms a complex with synde-
can-4 through a PDZ adaptor protein. In the absence of the
PDZ-binding motif of syndecan-4, and hence PDZ adaptor
binding, the phosphatase would no longer dephosphorylate
the PDZ
  mutant. This explanation applies both to the mem-
brane and the Golgi-associated syndecan-4 pools, since the cy-
toplasmic tail of the latter would protrude into the cytoplasm
and be accessible to the phosphatase and kinase.
The hyperphosphorylated PDZ
  mutant has reduced ten-
dencies to oligomerize and bind PIP2, resulting in a dimin-
ished capacity to activate PKC  (Horowitz and Simons,
1998a). Moreover, its presence in the plasma membrane may
interfere with the oligomerization, PIP2 binding, and activa-
tion of PKC  by dephosphorylated endogenous syndecan-4.
This loss of syndecan-4–dependent activation of PKC  in re-
sponse to FGF2 may then account for the dominant negative
effects of the PDZ
  mutation.
It should be noted that the lower activity of PKC  in the
presence of the PDZ
  peptide compared with the WT peptide
(Fig. 8 C) leaves open the possibility that the induction of a
dominant negative phenotype by the PDZ
  mutation can be
caused by reduction in PKC  activity, similar to the PIP2
 
cells. Although it is not obvious how deletion of a single
COOH-terminal residue in the cytoplasmic tail of syndecan-4
produces this effect, the deletion could conceivably affect the
conformation of the PIP2-binding motif and hence reduce its
affinity to PIP2.
FGF2 specificity of the syndecan-4 signaling pathway
Another intriguing observation in this study is the apparent
FGF2 specificity (versus serum, EGF, and PDGF) of the
syndecan-4 signaling pathway. This specificity may stem in
part from the choice of functional assays used in this study,
since both cell migration (Harrington et al., 1997) and pro-
liferation (Schonwasser et al., 1998; Besson and Yong, 2000)
have been linked to the activation of PKC , the kinase regu-
lated by syndecan-4. However, not all FGF2-induced signal-
ing events may necessarily be regulated in this fashion. The
fact that, unlike FGF2, serum stimulation of cell growth and
proliferation is not affected by the PIP2
 and PDZ
  synde-
can-4 mutants suggests that other growth factors present in
serum, such as EGF or PDGF AB, may stimulate cell
growth and migration independent of PKC . The lack of
increase in PIP2-dependent PKC  activation after serum
stimulation (Fig. 6 A) agrees with this observation.
Though all syndecans and glypicans can carry HS chains
and may, therefore, bind FGF2, only syndecan-4 selectively
modulates FGF2 signaling (Volk et al., 1999; Simons and
Horowitz, 2001). The unique nature of the syndecan-4–
dependent amplification of FGF2 signaling is related to the
presence of its cytoplasmic tail, since the expression of chi-
meras consisting of either glypican-1 (Volk et al., 1999) or
syndecan-1 (unpublished data) ectoplasmic domain fused to
the transmembrane and cytoplasmic domains of syndecan-4
mimics the positive effects of intact syndecan-4 overexpres-
sion on cell proliferation and migration. These findings, to-
gether with the results of the current study, suggest that PIP2
binding and the concomitant ability to activate PKC  un-
derlie the unique capacity of syndecan-4 among the cell sur-
face proteoglycans to regulate FGF2 signaling.724 The Journal of Cell Biology | Volume 157, Number 4, 2002
In summary, we describe a novel signal transduction pathway
that involves selective regulation of endothelial cell migration
and proliferation by FGF2 via syndecan-4.
Materials and methods
cDNA constructs, mutagenesis, and transfection
Syndecan-4 cDNA containing an ectoplasmic HA tag (Shworak et al.,
1994) was subcloned into MSCV retroviral vector (Hawley et al., 1994)
between its EcoRI and BglII sites. Site-directed mutations were intro-
duced into syndecan-4 cDNA by PCR-mediated oligomutagenesis
(QuikChange; Stratagene). The vector was delivered into RFPECs by ei-
ther retroviral (as described in Volk et al., 1999) or liposome-mediated
transfection (LipofectAmine Plus; Invitrogen). In both cases, stably trans-
fected cells were selected by neomycin resistance (0.4 mg/ml Geneticin;
Invitrogen). Syndecan-4 expression levels were assessed by immunoblot-
ting cell lysates as described (Horowitz and Simons, 1998a) with 50 mU/
ml HRP-conjugated 3F10 HA antibody (Roche).
Alternatively, the HA-tagged syndecan-4 cDNA constructs were in-
serted between the XhoI and EcoRI restriction sites of a bicistronic mam-
malian expression plasmid (pIRES2-EGFP; CLONTECH Laboratories) that
coexpresses EGFP and the inserted cDNA under a single promoter. RFPECs
were stably transfected by LipofectAmine 2000 (Invitrogen) and selected
by neomycin resistance as a pooled population. To enrich each pool with
cells having high expression levels of the transfected protein, only cells in
the top 2–5% of the population as determined by two to three consecutive
sorting rounds (see below) were retained and expanded.
Cell function assays
Cells were incubated as described (Horowitz and Simons, 1998a) in M199
medium (Invitrogen) with the indicated supplements. Cell migration was
measured by “wounding” assays (Tang et al., 1997) in which cells were
grown to subconfluence in 6-well plates and then starved for 24 h in 0.5%
serum. The cell layer was scratched with a pipette tip, producing a gap
 2-mm wide. The gap width was measured at marked locations from im-
ages taken by inverted microscope (TMS-F; Nikon) immediately after the
scratching and again 6 h later at the same locations. Proliferation and tube
formation assays were done as described (Volk et al., 1999). All experi-
ments were repeated with two clones of cells stably transfected with each
syndecan-4 variant. Neomycin was withdrawn from the culture medium at
least 24 h before the cell function assays and before all other experiments
with stably transfected RFPECs to prevent artifacts caused by neomycin se-
questration of PIP2 (Gabev et al., 1989).
FACS
To measure the amount of exogenous syndecan-4 present on the cell sur-
face, cells were dissociated from plates (nonenzymatic solution; Sigma-
Aldrich), labeled with 1  g/ml antibody to HA (Roche) followed by 10
 g/ml of anti–rat IgG conjugated to R-PE (Jackson Immunologicals), and
sorted automatically (FACScan
®; Beckton Dickinson). Detection of the
surface expression of both exogenous and endogenous syndecan-4 was
done similarly using a 1:50 dilution of antiserum to the ectoplasmic do-
main of syndecan-4 (Shworak et al., 1994) and 10  g/ml of anti–rabbit
IgG conjugated to Alexa-594 (Molecular Probes). To detect the overall
cellular expression of exogenous syndecan-4, cells were scanned at the
EGFP-emitted wavelength (488 nm).
Immunofluorescence
RFPECs were plated in chamber slides (Nunc), fixed with 2% formalde-
hyde in PBS (137 mM NaCl, 4.3 mM Na2HPO4   7H2O, 2.7 mM KCl, 1.4
mM KH2PO4, pH 7.3) for 10 min at room temperature, washed twice
with PBS, permeabilized with 0.1% Triton X-100/PBS for 10 min, washed
again as above, blocked with 3% BSA (Invitrogen) in PBS for 30 min, and
incubated with primary antibodies at the indicated concentrations in 1%
BSA in PBS for 3 h. The slides were washed four times as above and in-
cubated for 1 h with 10  g/ml of the appropriate secondary antibodies
conjugated either to Alexa 488 or Alexa 594 (Molecular Probes), washed
again as before, and mounted with ProLong medium (Molecular Probes).
Slides were imaged by laser-scanning confocal microscopy (Radiance2000;
Bio-Rad Laboratories, Inc.).
Immunoprecipitation
Cells were lysed and immunoprecipitated as described (Horowitz and Si-
mons, 1998a,b) using 80  l anti-HA affinity matrix (Roche) suspension
per 750  l cell lysate. Alternatively, endogenous or HA-tagged synde-
can-4 was immunoprecipitated with 10  l cytoplasmic tail antiserum
(Shworak et al., 1994) or with 5  g HA antibody (3F10; Roche) per 750
 l cell lysate, respectively, and 40  l suspension of protein G plus/pro-
tein A agarose (Oncogene). Where indicated, glycosaminoglycan chains
were digested as described (Horowitz and Simons, 1998b).
Surface plasmon resonance
Experiments were performed as described (Horowitz et al., 1999) using
28–amino acid–long (Horowitz and Simons, 1998a) syndecan-4 cyto-
plasmic tail peptides (Genemed Synthesis) as ligands and PIP2 (Sigma-
Aldrich) as analyte.
Column chromatography
Synthetic syndecan-4 cytoplasmic tail peptides (1  M) either alone or
mixed with PIP2 (2  M) in 0.1 M phosphate, pH 7.4, and 20% acetonitrile
were injected (22.5  l) into a 300   6 mm silica (5  m spheres, 60 Å
pores) HPLC (Waters, 515 Pump, 2487 Absorbance Detector)-mounted
column (YMC). Elution profiles corresponding to light absorbance at 210
nm were recorded digitally (Millennium
32; Waters).
Kinase assays
With recombinant PKC . These were performed either in the presence of
PIP2 or Ca
2 , phosphatidylserine, and diolein as described (Horowitz and
Simons, 1998a) using recombinant PKC  (120 ng/ml). Kinase activity was
quantified by phosphoimaging (Molecular Dynamics) of gel-resolved
PKC I optimal substrate peptide bands. PKC autoinhibitor peptide and
Gö6976 were purchased from Calbiochem.
With immunoprecipitated syndecan-4. Syndecan-4 complexes immuno-
precipitated as described above with 5  g HA antibody per 750  l cell ly-
sate and 40  l protein G plus/protein A agarose suspension were used for
in vitro kinase assays. After washing in 25 mM Tris-HCl (pH 7.4) buffer, the
beads were sedimented, and the buffer was removed and replaced with 30
ml kinase assay buffer containing either PIP2 or Ca
2 , phosphatidylserine,
and diolein as described (Horowitz and Simons, 1998a). The assay was
stopped by adding 10  l  4 Laemmli sample buffer (final concentration
2% SDS, 10% glycerol, 0.5%  -mercaptoethanol, 0.004% bromophenol
blue, 50 mM Tris-HCl, pH 6.8) and boiling for 4 min. Kinase activity was
quantified as in the recombinant PKC  assays.
Measurement of syndecan-4 phosphorylation level
RFPECs in 100-mm plates were grown for 24 h in phosphate-free DME (Invi-
trogen) supplemented with 0.5% FBS and radiolabeled for 4 h with 0.5 mCi/
ml [
32P]orthophosphoric acid (New England Nuclear). Cells were washed with
tris-buffered saline (137 mM NaCl, 25 mM Tris-HCl, pH 7.4) and scraped off
in 0.5 ml lysis buffer (150 mM NaCl, 20 mM NaF, 20 mM Na4P2O7, 5 mM
EDTA, 5 mM EGTA, 1 mM Na3VO4, 1 mM PMSF, 1% Triton X-100, 50 mM
Hepes, pH 7.4) supplemented with protease inhibitor cocktail (Complete;
Boehringer). Cell lysates were precleared by incubation with 1  g nonim-
mune rat IgG (Sigma-Aldrich) and 20  l protein G plus/protein A agarose bead
suspension at 4 C for 1 h. After agarose bead sedimentation, the cleared sam-
ples were supplemented with 80  l of anti-HA affinity matrix bead suspension
(Roche) or with 10  l cytoplasmic tail antiserum (Shworak et al., 1994) and 40
 l suspension of protein G plus/protein A agarose (Oncogene) and incubated
in rotating tubes over night at 4 C. The beads were sedimented, washed three
times in heparinase digestion buffer (50 mM NaCl, 4 mM CaCl2, 20 mM Tris-
HCl, pH 7.4), and glycosaminoglycan chains were digested as described
(Horowitz and Simons, 1998b). The immunoprecipitated syndecan-4 core
protein was dissociated from the beads by a 10-min incubation in 40  l Laem-
mli sample buffer at 95 C. Samples were resolved on 12% tris-glycine gels
(Bio-Rad Laboratories), and the bands corresponding to the cytoplasmic tail of
syndecan-4 were identified by immunoblotting with a peroxidase-conjugated
antibody to the HA tag (Roche). The bands were excised, and the 
32P level was
measured by scintillation counter (Beckman Coulter).
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